NUCLIDIUM

NUCLIDIUM's vision is to address the unmet need in cancer medicine by providing personalised treatment options for cancer patients at every stage of their disease to improve long-term survival. Our therapeutic approach combines accurate diagnosis and staging of cancers at an early stage with a highly personalized treatment dose enabling less aggressive treatment and a significantly better quality of life for the patient... Our therapeutic portfolio includes personalised treatment strategies for key solid tumour indications with high need for innovation... NUCLIDIUM's mission is to provide personalised therapy for cancer patients at every stage of their disease.

Also known as: Nuclidium AG, Nuclidium GmbH

Registration numbers: HRB 262606 (W)

VAT numbers: DE342413979

Primary location: Basel Switzerland